PHASE II TRIAL OF FOLFOX6, BEVACIZUMAB AND CETUXIMAB IN PATIENTS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 目的：探讨FOLFOX6、贝伐单抗和西妥昔单抗联合治疗晚期结直肠癌的安全性、给药可行性、疗效和生存率。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine the safety, feasibility of administration, response and survival rates among patients with advanced colorectal cancer treated with the combination of drugs, Folfox6, Bevacizumab and Cetuximab.